Pillar Biosciences

Targeted next-generation sequencing (NGS)-based assays and software

Pillar Biosciences improving next-generation sequencing (NGS) tools to advance precision medicine. Speed and accuracy are required for disease diagnostics, but they are often incompatible. Rapid advances in NGS have reduced the cost and speed of genomic sequencing, but improvements can still be made to reduce errors and enable multiplexing. Pillar’s SLIMamp and PiVAT technologies deliver robust, reliable and rapid clinical results and enable actionable clinical treatment decisions. Pillar has received FDA approval for its oncoReveal Dx Lung and Colon Cancer Assay, which helps identify non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) patients who will benefit from specific therapies. Pillar’s mission is to apply precision medicine throughout a patient’s journey.